Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results ...
Hosted on MSN45m
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Eli Lilly on Tuesday lowered guidance for its December quarter amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. Eli Lilly stock tumbled on the news. For the December ...
Eli Lilly was hoping for even greater weight loss drug demand
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...